Home / Technical Content / Merck & Co. Case Study: Advancing Greener Chemistry for the Next Generation of HIV Treatments
See What’s Possible When Pharma Biocatalysis Meets Commercial-scale Execution
Discover how Merck & C0. partnered with Codexis to advance an innovative biocatalytic manufacturing route for islatravir, replacing a 16-step clinical supply route with a three-step process featuring a nine-enzyme cascade. Codexis helped engineer seven of those enzymes and delivered them at commercial scale in just five months, supporting demonstration of the process at 100 kg scale.
Download the case study to explore the science, collaboration and manufacturing execution behind a new approach to sustainable pharmaceutical production.
Gated content
Please complete the form below to access this content.
Discover the Expertise Powering Possibility
Speak to our experts to learn how our platforms deliver smarter science, faster timelines, and greater confidence. Let’s talk.
Related Content
Case Study: Scale siRNA Manufacturing via Ligation with Bachem
Want to see more technical content?
We're Paving Your Path to the Future
You own the product and we own the path. Together, we’ll take it to market clearly, cleanly and without surprises.